Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30033709 | 1.00 | KCNN4 (0.34) | KCNN4CTSLCTSSCTSKPTPN1 | |
| SCHEMBL23043456 | 0.86 | KCNN4 (0.34) | KCNN4PTPN1MEN1KMT2ATDP1 | |
| SCHEMBL29428708 | 0.86 | KCNN4 (0.34) | KCNN4PTPN1MEN1KMT2ATDP1 | |
| SCHEMBL11926107 | 0.82 | PTPN1 (0.41) | PTPN1MEN1KMT2ATDP1HPGD | |
| SCHEMBL20608004 | 0.79 | L3MBTL1 (0.42) | KCNN4PTPN1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL29381303 | 0.79 | L3MBTL1 (0.42) | KCNN4PTPN1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL23043154 | 0.77 | BACE1 (0.34) | CYP3A4 | |
| SCHEMBL30033024 | 0.77 | BACE1 (0.34) | CYP3A4 | |
| SCHEMBL31166945 | 0.77 | PTPN1 (0.42) | KCNN4PTPN1TDP1L3MBTL1KDM4E | |
| SCHEMBL12189941 | 0.76 | KDM1A (0.49) | MEN1KMT2ATDP1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | GENENTECH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4526309-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | BIOMEA FUSION, INC. | 2024-12-12 | — | — | US | disclosed |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-116057059-B | Deuterated compounds useful as KRAS G12D inhibitors | 南京燧坤智能科技有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023225302-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-116731044-A | Pyrimidine-containing polycyclic biological inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230279025-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-09-07 | — | — | US | disclosed |
| WO-2023039240-A9 | IRREVERSIBLE INHIBITORS OF KRas | BIOMEA FUSION, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| CN-116057059-A | Deuterated compounds useful as KRAS G12D inhibitors | 南京燧坤智能科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279025-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | KCNN4 4820/4885CTSL 2331/4885CTSS 1676/4885 |
| US-12338256-B2 | Aza-tetracyclic oxazepine compounds and uses thereof | AZI2, TET3, OXA1L | KCNN4 535/4885CTSL 3678/4885CTSS 4361/4885 |
| US-20240409558-A1 | IRREVERSIBLE INHIBITORS OF KRAS | KRAS, NRAS, TP53 | KCNN4 3890/4885CTSL 3958/4885CTSS 2733/4885 |
| US-20240025919-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | KCNN4 535/4885CTSL 3678/4885CTSS 4361/4885 |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | KCNN4 133/4885CTSL 3905/4885CTSS 3608/4885 |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | KCNN4 4827/4885CTSL 3662/4885CTSS 2556/4885 |
| US-20240368186-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | AZI2, TET3, OXA1L | KCNN4 535/4885CTSL 3678/4885CTSS 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.